{'fraction_non_alphanumeric': 0.015503875968992248, 'fraction_numerical': 0.012058570198105082, 'mean_word_length': 5.020725388601036, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long-lasting clinical benefit of sunitinib malate in the treatment of a case of heavily pre-treated metastatic liposarcoma.

BACKGROUND
Soft tissue sarcomas are a heterogeneous group of malignant neoplasms including several distinct entities with different cell differentiation and clinical prognosis, but which are often treated as a single disease.


CASE REPORT
We report the case of a male patient, heavily treated for a metastatic well-differentiated liposarcoma occurring in the left lateral neck. He received radiotherapy and different lines of standard chemotherapy with local progression and lung metastasis. In November 2009, on the basis of a phase II study demonstrating the efficacy of sunitinib in patients with liposarcoma, the patient was treated with sunitinib at 37.5 mg daily in 4-week cycles on a compassionate use basis. Until November 2012 he received a total of 23 cycles of sunitinib treatment achieving a stable disease in all sites. Therapy with sunitinib is still ongoing without side effects.


CONCLUSION
Our findings confirm that sunitinib may be a useful therapeutic tool in the treatment of some cases of pre-treated liposarcoma.